Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM)

Bone Marrow Transplantation

Volumn 29, Issue 12, 2002, Pages 943-947

  Anagnostopoulos, A ^a   Giralt, S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

High chemotherapy; Stem cell; Transplantation; Waldenstrom's macroglobulinemia

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN M; MELPHALAN; NUCLEOSIDE ANALOG; PARAPROTEIN; THIOTEPA;

ADULT; AGE DISTRIBUTION; AGED; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; GERIATRIC PATIENT; GRAFT FAILURE; HUMAN; HUMAN CELL; HYPERVISCOSITY SYNDROME; IDIOPATHIC DISEASE; LYMPHADENOPATHY; MONOTHERAPY; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; REVIEW;

ADULT; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 0036327182     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703580     Document Type: Short Survey

References (33)

1. Waldenstrom's macroglobulinemia: Clinical features, complications, and management
2. Study of prognosis in Waldenstrom's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility
3. Prognostic factors in Waldenstrom's macroglobulinemia: A report of 167 cases
4. Waldenstrom's macroglobulinemia
5. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: Results of United States intergroup trial
6. Treatment of Waldenstrom's macroglobulinemia with very low doses of alpha interferon
7. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenstrom's macroglobulinaemia
8. Treatment of Waldenstrom's macroglobulinemia with thalidomide
9. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia
10. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia
11. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia
12. Total therapy with VAMP/CVAMP+ high dose melphalan and autograft for IgM lymphoplasmacytoid disease
13. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: An interim report
14. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinemia with severe pancytopenia
15. Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia
16. Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia
17. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine
18. First-line treatment of Waldenstrom's disease with cladribine
19. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors
20. Cladribine for Waldenstrom's macroglobulinaemia
21. Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinaemia
22. Patients with the description of a new scoring system and its validation on 253 other patients
23. Fludarabine phosphate in lymphoma: An important new therapeutic agent
24. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment
25. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies
26. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients
27. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): A report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on EBMT Chronic Leukaemias Working Party (CLWP)
28. Transplant-lite: Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
29. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
30. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus- tumor effects
31. Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: Past accomplishments and future goals
32. Allogeneic bone marrow transplantation for poor prognosis lymphoma: Response, toxicity and survival depend on disease histology
33. Transplant-lite using fludarabine cyclophosphamide and allogeneic stem cell transplant for low grade lymphoma